Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates
Ruth Hunegnaw, Anna N. Honko, Lingshu Wang, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 675
Closed Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

An introduction to the Marburg virus vaccine consortium, MARVAC
Robert W. Cross, Ira M. Longini, Stephan Becker, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 10, pp. e1010805-e1010805
Open Access | Times Cited: 47
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
Melinda Hamer, Katherine V. Houser, Amelia R. Hofstetter, et al.
The Lancet (2023) Vol. 401, Iss. 10373, pp. 294-302
Open Access | Times Cited: 41
Emergence of Marburg virus: a global perspective on fatal outbreaks and clinical challenges
Shriyansh Srivastava, Deepika Sharma, Sachin Kumar, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 36
From protein to immunology: comprehensive insights into Marburg virus vaccines, mechanism, and application
Mohamed J. Saadh, Faris Anad Muhammad, Rafid Jihad Albadr, et al.
Archives of Microbiology (2025) Vol. 207, Iss. 4
Closed Access | Times Cited: 1
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial
Betty Mwesigwa, Katherine V. Houser, Amelia R. Hofstetter, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 12, pp. 1408-1417
Closed Access | Times Cited: 17
Strengthening Global Health Resilience: Marburg Virus-Like Particle Vaccines and the One Health Approach
Ram Bahadur Khadka, Khimdhoj Karki, Jitendra Kumar Pandey, et al.
Science in One Health (2024) Vol. 3, pp. 100076-100076
Open Access | Times Cited: 6
Filovirus vaccines as a response paradigm for emerging infectious diseases
Andrea Marzi, Heinz Feldmann
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels
Machteld M. Tiemessen, Laura Solforosi, Liesbeth Dekking, et al.
Vaccines (2022) Vol. 10, Iss. 8, pp. 1263-1263
Open Access | Times Cited: 21
A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus
Courtney Woolsey, Viktoriya Borisevich, Krystle N. Agans, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_7, pp. S660-S670
Closed Access | Times Cited: 12
Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses.
Alexander Bukreyev, Michelle Meyer, Bronwyn M. Gunn, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 4
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans
Chelsea McLean, Karin Dijkman, Auguste Gaddah, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
A Surrogate BSL2-compliant Infection Model Recapitulating Key Aspects of Human Marburg Virus Disease
Wanying Yang, Wujie Zhou, Bo Liang, et al.
Emerging Microbes & Infections (2025)
Open Access
Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial
Daniel Jenkin, Rebecca Makinson, Helen Sanders, et al.
The Lancet Microbe (2025), pp. 101022-101022
Open Access
Mapping knowledge landscapes and emerging trends of Marburg virus: A text-mining study
Yuanjun Lyu, Wanqing Li, Qiang Guo, et al.
Heliyon (2024) Vol. 10, Iss. 8, pp. e29691-e29691
Open Access | Times Cited: 3
Vaccine Licensure in the Absence of Human Efficacy Data
Courtney L. Finch, Christian Martinez, Elizabeth K. Leffel, et al.
Vaccines (2022) Vol. 10, Iss. 3, pp. 368-368
Open Access | Times Cited: 14
Designing a novel and combinatorial multi-antigenic epitope-based vaccine “MarVax” against Marburg virus—a reverse vaccinology and immunoinformatics approach
Bishal Debroy, Sribas Chowdhury, Kuntal Pal
Journal of Genetic Engineering and Biotechnology (2023) Vol. 21, Iss. 1, pp. 143-143
Open Access | Times Cited: 7
Sudan virus disease – A quick review
Tsung-Pei Tsou
Journal of the Formosan Medical Association (2023) Vol. 123, Iss. 1, pp. 16-22
Open Access | Times Cited: 6
Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection
Albert To, Teri Ann S. Wong, Aquena H. Ball, et al.
Vaccine (2023) Vol. 42, Iss. 3, pp. 598-607
Closed Access | Times Cited: 5
Bridging Animal and Human Data in Pursuit of Vaccine Licensure
Courtney L. Finch, William E. Dowling, Thomas H. King, et al.
Vaccines (2022) Vol. 10, Iss. 9, pp. 1384-1384
Open Access | Times Cited: 8
Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs
Courtney L. Finch, Thomas H. King, Kendra J. Alfson, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1935-1935
Open Access | Times Cited: 8
A Single-shot ChAd3 Vaccine Provides Protection from Intramuscular and Aerosol Sudan Virus Exposure
Anna N. Honko, Ruth Hunegnaw, Juan I. Moliva, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
Alina Tscherne, Georgia Kalodimou, Alexandra Kupke, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1316-1316
Open Access | Times Cited: 1
The looming threat of Marburg disease outbreak in Tanzania, East Africa – an Editorial
Malik Olatunde Oduoye, Kanza Farhan, Muhammad Burhan Tariq, et al.
Annals of Medicine and Surgery (2023) Vol. 85, Iss. 9, pp. 4194-4196
Open Access | Times Cited: 1
"Pros and Cons of Viral Zoonotic Diseases: A Public Health Nutrition Perspective and Policy Implication in Nigeria"
Paulina Oludoyin Adeniyi
Biomedical Journal of Scientific & Technical Research (2023) Vol. 52, Iss. 4
Open Access | Times Cited: 1
ADVANCEMENTS IN MARBURG VIRUS VACCINE DEVELOPMENT: UNRAVELLING RECENT FINDINGS. A NARRATIVE REVIEW.
Amna Zaheer
(2024)
Open Access
Page 1 - Next Page

Scroll to top